Publicações

Lista com todas as publicações que tiveram a contribuições do Drº Guilherme Harada.

Publicações

  1. Reis-Alves SC, Traina F, Harada G, Campos PM, Saad STO, Metze K, Lorand-Metze I. Immunophenotyping in Myelodysplastic syndromes can add prognostic information to well-established and new clinical scores. PLoS One. 2013 Dec 6;8(12):e81048. doi: 10.1371/journal.pone.0081048. eCollection 2013.
    Link: https://doi.org/10.1371/journal.pone.0081048

  2. Harada G, Felipe-Silva A ; Silva JGN. Early stage primary gastric diffuse large B-cell lymphoma in a young HIV-positive patient. AUTOPSY AND CASE REPORTS, v. 4, p. 49-54, 2014. doi: https://doi.org/10.4322/acr.25y.82535
    Link: http://dx.doi.org/10.4322/acr.2014.014

  3. Bonadio RRCC; Azevedo RGMV, Harada G, Costa SCS, Miranda VC, Freitas D, Abdo Filho E; Ferrira PAO, Gabrielli F, Estevez Diz MDP. Adjuvant Carboplatin and Paclitaxel Cemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis. J Glob Oncol. 2018 Sep;4:1-8. doi: 10.1200/JGO.17.00146.
    Link: https://doi.org/10.1200/JGO.17.00146.

  4. Castro Junior G, Harada G, Mello ES. The importance of molecular characterization in lung cancer. Editorial. Brazilian Journal of Pneumology. 2019 Jun 3;45(3):e20190139. doi: 10.1590/1806-3713/e20190139.
    Link: https://doi.org/10.1590/1806-3713/e20190139

  5. Harada G, Bonadio RRCC, Araújo FCC, Victor CR, Sallum RAA, Junior UR, Cecconello I, Takeda FR, de Castria TB. Induction chemotherapy for locally advanced esophageal cancer. J Gastrointest Cancer. 2019 Jun 25. doi: 10.1007/s12029-019-00266-1.
    Link: https://doi.org/10.1007/s12029-019-00266-1

  6. Harada G, Santini FC, Canedo FSNA, Oliveira LJC, Zuppani HP, Castro Jr G. Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure. Ecancer 2019. 13:970 https://doi.org/10.3332/ecancer.2019.970
    Link: https://doi.org/10.3332/ecancer.2019.970

  7. Ribeiro TB, Ribeiro A, Rodrigues LO, Harada G, Nobre MRC. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer. Int J Technol Assess Health Care. 2019 Nov 28:1-9. doi: 10.1017/S0266462319000813.
    Link: https://doi.org/10.1017/S0266462319000813

  8. Harada G, Gongora ABL, Costa CM, Santini FC. NTRK Inhibitors in Non-Small Cell Lung Cancer. Curr. Treat. Options in Oncol. 21, 39 (2020).
    Link: https://doi.org/10.1007/s11864-020-00741-z

  9. Harada, G.; Bonadio, RRCC ; Marta, G. N. ; Recchimuzzi, D. Z. ; Castro Junior, G . Central Nervous System Metastases of Lung Adenocarcinoma Harboring EGFR-Activating Mutations: Survival Results from A Multidisciplinary Approach, Including EGFR-TKIs. Brazilian Journal of Oncology, VOL 16, January-December 2020.
    Link: https://doi.org/10.5935/2526-8732.20200011

  10. Machado MCM, Harada G, Castro G Jr. Autoimmunity as a paraneoplastic manifestation. Rev Paul Reumatol. 2020 jan-mar;19(1):7-12. DOI:https://doi.org/10.46833/reumatologiasp.2020.19.1.7-12.
    Link: https://doi.org/10.46833/reumatologiasp.2020.19.1.7-12

  11. da Costa CM, de Souza ZS, Real Salgues AC, Harada G, Marino Rodrigues Ayres PP, Vieira Nunes DB, Katz A, Munhoz RR. COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy. Immunotherapy. 2020 Oct;12(15):1133-1138. doi: 10.2217/imt-2020-0193.
    Link: https://www.doi.org/10.2217/imt-2020-0193

  12. Harada G, Antonacio FF, Gongora AB, Behar MH, Capareli FC, Bastos DA, Munhoz RR, Costa FP, Jardim DL, Arrais-Rodrigues C, Novis Y, Katz A, de Castro Junior G. SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review. Ecancermedicalscience. 2020 Sep 9;14:1100. doi: 10.3332/ecancer.2020.1100.
    Link: https://www.doi.org/10.3332/ecancer.2020.1100

  13. Angel MO, Colombo Bonadio R, Harada G On behalf of the Latin American Consortium for Lung Cancer Investigation (CLICaP) and Latin American Oncology Group (LACOG), et al Mentoring as an opportunity to improve research and cancer care in Latin America (AAZPIRE project). ESMO Open 2020;5:e000988. doi: 10.1136/esmoopen-2020-000988
    Link: https://www.doi.org/10.1136/esmoopen-2020-000988

  14. Harada G, Amano MT, Antonacio FF, Behar MH, Nabuco-De-Araujo PHX, Buchpiguel CA, Castro Junior G. Dramatic response to pembrolizumab monotherapy in a patient with ARID1A-mutant lung adenocarcinoma: case report. Clinical Lung Cancer 2021 Sep;22(5):e708-e711.  doi: 10.1016/j.cllc.2021.01.011.
    Link: https://www.doi.org/10.1016/j.cllc.2021.01.011

  15. Harada G, Neffa MFBV, Bonadio RRC, Mendoza EZ, Caparica R, Lauricella, LL ; Takagaki T. Y.,  Roitberg, F. S. R.; Terra, R. M.; Castro Junior, G, Effectiveness and toxicity of adjuvant chemotherapy in patients with non-small cell lung cancer. Brazilian Journal of Pulmonology. 2021 Feb 24;47(3):e20200378.  doi: 10.36416/1806-3756/e20200378.
    Link: https://www.doi.org/10.36416/1806-3756/e20200378

  16. Harada G, Santini FC, Wilhelm C, Drilon A. NTRK fusions in lung cancer: From biology to therapy. Lung Cancer. Volume 161, P108-113, November 01, 2021. 
    Link: https://doi.org/10.1016/j.lungcan.2021.09.005

  17. Antonacio FF, Harada G, Vilela RS, Freitas TC, Lima Jr JV, Kowalski LP, Almeida MQ, Castro Jr G. Cushing’s syndrome due to ectopic adrenocorticotropin secretion by a metastatic parotid carcinoma. Arch. Endocrinol. Metab., Jan. 2022. DOI: 10.20945/2359-3997000000426
    Link: https://www.doi.org/10.20945/2359-3997000000426

  18. Xavier CB, Lopes CDH, Harada G, Riera R, Dante E, Katz A, Jardim DLF. Cardiovascular toxicity incidence following immune checkpoint inhibitors in randomized clinical trials: a systematic review and meta-analysis. Transl Oncol. 2022 May;19:101383. doi: 10.1016/j.tranon.2022.101383. Epub 2022 Mar 3. PMID: 35248919; PMCID: PMC8898968.
    Link: https://www.doi.org/10.1016/j.tranon.2022.101383

  19. Murciano-Goroff Y, Harada G, Drilon A. An ascendant challenge: central nervous system metastases in ALK+ lung cancers. Clin Cancer Res. 2022 Apr 8;clincanres.0341.2022.  doi: 10.1158/1078-0432.CCR-22-0341.
    Link: https://www.doi.org/10.1158/1078-0432.CCR-22-0341

  20. Harada G, Drilon A. TRK Inhibitor Activity and Resistance in TRK Fusion-Positive Cancers in Adults. Cancer Genet. 2022 Jun;264-265:33-39. doi: 10.1016/j.cancergen.2022.03.002. Epub 2022 Mar 16. PMID: 35334340; PMCID: PMC9133157.
    Link: https://www.doi.org/10.1016/j.cancergen.2022.03.002

     

  21. Ambrosini M, Del Re M, Manca P, Hendifar A, Drilon A, Harada G, Ree AH, Klempner S, Malandsmo GM, Flatmark K, Russnes HG, Cleary JM, Singh H, Sottotetti E, Martinetti A, Randon G, Sartore-Bianchi A, Capone I, Milione M, Di Bartolomeo M, Pietrantonio Filippo. ALK inhibitors in patients with ALK fusion positive gastrointestinal cancers: an international dataset and a molecular case series.  JCO Precis Oncol. 2022 Apr;6:e2200015. doi: 10.1200/PO.22.00015. PMID: 35476549.
    Link: https://www.doi.org/10.1200/PO.22.00015

  22. Awni BM, Holanda Lopes CD, Harada G, Salgues ACR, França GA, Testagrossa LA, Queiroz MA, Gonçalves E Silva A, Ferreira FO, Munhoz RR. Exacerbated Renal and Hematologic Toxicities to Ifosfamide and Doxorubicin-Based Chemotherapy in a Patient with Retroperitoneal Liposarcoma Harboring a Germline Mutation in the WRN Gene. Case Rep Oncol. 2022 Mar 4;15(1):170-175. doi: 10.1159/000521624. PMID: 35431856; PMCID: PMC8958610.
    Link: https://www.doi.org/10.1159/000521624

  23. Force BSoCOT. Editorial coordinators and final review: Munhoz RR, Mathias CMC, Harada G, Clara RO. Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors – edition 2.0. Braz J Oncol. 2022;18:e-20220305. May 6 2022 DOI: 10.5935/2526-8732.20220305
    Link: https://www.doi.org/10.5935/2526-8732.20220305

     

  24. Kalchiem-Dekel O, Falcon CJ, Bestvina CM, Liu D, Kaplanis LA, Wilhelm C, Eichholz J, Harada G, Wirth LJ, Digumarthy SR, Lee RP, Kadosh D, Mendelsohn RB, Donington J, Gainor JF, Drilon A, Lin JJ. Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. J Thorac Oncol. 2022 Jul 1:S1556-0864(22)00312-4. doi: 10.1016/j.jtho.2022.06.008. Epub 3033 Jul 3. PMID: 35788405.
    Link: https://www.doi.org/10.1016/j.jtho.2022.06.008

  25. Calvo E, Sessa C, Harada G, de Miguel M, Kahatt C, Luepke-Estefan XE, Siguero M, Fernandez-Teruel C, Cullell-Young M, Stathis A, Drilon A. Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors. Invest New Drugs. 2022 Dec;40(6):1263-1273. doi: 10.1007/s10637-022-01281-z. Epub 2022 Aug 10. PMID: 35947247
    Link: https://www.doi.org/10.1007/s10637-022-01281-z

     

  26. Harada G, Yang SR, Cocco E, Drilon A. Rare molecular subtypes of lung cancer. Nat Rev Clin Oncol. 2023 Apr;20(4):229-249. doi: 10.1038/s41571-023-00733-6. Epub 2023 Feb 20. PMID: 36806787.
    Link: https://www.doi.org/10.1038/s41571-023-00733-6

     

  27. Rotow J, Patel JD, Hanley MP, Yu H, Awad M, Goldman JW, Nechushtan H, Scheffler M, Kuo CS, Rajappa S, Harada G, Clifford S, Santucci A, Silva L, Tupper R, Oxnard GR, Kherani J, Drilon A. Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers. Clin Cancer Res. 2023 Mar 30:CCR-22-2189. doi: 10.1158/1078-0432.CCR-22-2189. PMID: 36996322.
    Link: https://www.doi.org/10.1158/1078-0432.CCR-22-2189

     

  28. Malini M. Gandhi, Biagio Ricciuti, Guilherme Harada, Matteo Repetto, Melissa Gildenberg, Ankit Singh, Yvonne Y. Li, Andreanne Gagne, Xinan Wang, Ayal Aizer, Kelly Fitzgerald, Mizuki Nishino, Joao Alessi, Federica Pecci, Alessandro Di Federico, Adam Fisch, Alexander Drilon, Valentina Nardi, Lynette Sholl, Mark M. Awad*, Julia Rotow. Amplification of wild-type RET represents a novel molecular subtype of several cancer types with clinical response to selpercatinib. JCO Precis Oncol. 2023
    Link: https://doi.org/10.1200/po.23.00295

     

  29. Chen MF, Harada G, Liu D, DeMatteo R, Falcon C, Wilhelm C, Kris MG, Drilon A, Gutgarts V. Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to “False” Decreases in Renal Function. J Thorac Oncol. 2023 Sep 23:S1556-0864(23)02247-5. doi: 10.1016/j.jtho.2023.09.1444. Epub ahead of print. PMID: 37748692.
    Link: https://www.doi.org/10.1016/j.jtho.2023.09.1444

Apresentações

  1. Reis-Alves SC ; Pereira-Cunha FG; Rocha, FF; Harada G ; Traina F; Saad STO, Lorand-Metze I. Comparison of Classical and New Prognostic Factors in Myelodysplastic Syndromes. Rev Bras Hematol Hemoter. Novembro 2011;33 (supl. 2):33-293. Presented in Brazilian Congress of Hematology and Hemotherapy, 2011 – Sao Paulo, Brazil

  2. Lorand-Metze I, Reis-Alves SC , Campos PM, Harada G, Saad STO,  TRAINA F. The impact of old and new prognostic features on the survival of patients with MDS. Haematologica. Pavia-Italy: Ferrata-Storti Foundation, 2012. v. 97. p. 579-579. Presented in 17th Congress of the European Hematology Association – Amsterdam, Netherlands

  3. Reis-Alves SC, Harada G, Rocha FF; Pereira-Cunha FG, Traina F, Saad STO, Lorand-Metze I. Evaluation of two phenotypic scores and its importance in the differential diagnosis between MDS and NON-CLINIICAL cytopenias. Revista Brasileira de Hematologia e Hemoterapia (Impresso). São Paulo: RS Press Editora, 2012. v. 34. p. 321-321. Presented in Brazilian Congress of Hematology and Hemotherapy, 2012 – Rio de Janeiro, Brazil

  4. Reis-Alves SC, Harada G, Pereira-Cunha FG, Rocha FF, Saad STO, Traina F Lorand-Metze I. Comparison of old and new prognostic factors in Myelodysplastic syndromes. Leukemia Research, 2013. v. 37. p. s76-s76. Presented in 12th International Symposium on Myelodysplastic Syndromes (MDS) – Berlin, Germany
    Link: https://doi.org/10.1016/S0145-2126(13)70165-6

  5. Gomes F, Harada G, Stylianou K, Lorigan P. Age effect on advanced melanoma treatment options. Presented in 7th European Pos-Chicago Melanoma/ Skin Cancer Meeting 2017 –   Munich, Germany

  6. Bonadio RRCC; Azevedo RGMV, Harada G, Costa SCS, Miranda VC, Freitas D, Abdo Filho E; Ferrira PAO, Gabrielli F, Estevez Diz MDP. Adjuvant Carboplatin and paclitaxel chemotherapy followed by radiotherapy in high-risk endometrial cancer: A retrospective analysis JCO 2017 35:15_suppl, e17115-e17115. Abstract ASCO 2017 – Chicago, USA
    Link: https://doi.org/10.1200/jgo.17.00146

  7. Harada G, Bonadio RRCC, Marta GN, Takahashi TK, Takagaki T, Castro Jr G. CNS Metastases of Pulmonary Adenocarcinoma Harboring EGFR-Activating Mutations: a Multidisciplinary Approach, Including EGFR-Tkis. Journal of Thoracic Oncology, Vol. 12, Issue 11, S2226–S2227. Presented in IALSC –  2017  – Yokohama, Japan
    Link: https://doi.org/10.1016/j.jtho.2017.09.1507

  8. Victor CR; Fujiki FK; Zakon DB; Harada G;  Castria TB. Toxicity and efficacy of chemotherapy in patients with metastatic esophageal cancer treated in the community. Braz J Oncol. 2017; 13(Supl): 1-402. Presented in Brazilian Congress of Clinical Oncology 2017 – Rio de Janeiro, Brazil

  9. Bonadio RRCC; Azevedo RGMV, Harada G, Miranda VC, Freitas D, Abdo Filho E; Ferrira PAO, Gabrielli F, Estevez Diz MDP, Costa SCS. Adjuvant Carboplatin and paclitaxel chemotherapy followed by radiotherapy in high-risk endometrial cancer: Impact of high hitological grade. Braz J Oncol. 2017; 13(Supl): 1-402. Presented in Brazilian Congress of Clinical Oncology 2017 – Rio de Janeiro, Brazil
    Link: https://doi.org/10.1200/jgo.17.00146

  10. Bonadio RRCC, Harada G, Marta GN, Mak M, Martins RE, Yae T, Castro Junior G. CNS Metastases of Pulmonary Adenocarcinoma Harboring EGFR-Activating Mutations: Clinical presentation and mutations profile. Braz J Oncol. 2017; 13(Supl): 1-402. Presented in Brazilian Congress of Clinical Oncology 2017 – Rio de Janeiro, Brazil

  11. Harada G, Bonadio RRCC, Victor CR, Araújo FCC, Takeda FR, Junior UR, Cecconello I, de Castria TB. Induction chemotherapy for locally advanced esophageal cancer. Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282. ESMO 2018 – Munich, Germany
    Link: https://doi.org/10.1093/annonc/mdy282

  12. Roitberg FSR, Neffá MFBV, Bonadio RRCC, Harada G et al. Efficacy and safety of adjuvant chemotherapy in lung cancer: Real-world evidence. Annals of Oncology, Volume 30, Issue Supplement_2, April 2019, mdz067.015, https://doi.org/10.1093/annonc/mdz067.015.  European Lung Cancer Congress (ELCC) 10–13 April 2019, Geneva, Switzerland.
    Link: https://doi.org/10.1093/annonc/mdz067.015

  13. Xavier CB, Lopes CDH, Harada G, Katz A, Jardim DLF. Cardiovascular toxicity incidence following immune checkpoint inhibitors in randomized clinical trials: A systematic review and meta-analysis. Journal of Clinical Oncology 2021 39:15_suppl, 2636-2636 . ASCO 2021.
    Link: https://doi.org/10.1200/JCO.2021.39.15_suppl.2636

  14. Castro Jr. G, Kashiura D, Harada G, Torres LL, Codima A, Monteiro G, Costa IG, Julian GS STK11 and KEAP1 mutational status and their impact in survival outcomes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: Meta-analyses of clinical trials and cohort studies. Annals of Oncology (2021) 32 (suppl_5): S829-S866. 10.1016/annonc/annonc705. ESMO 2021.
    Link: https://doi.org/10.1016/j.annonc.2021.08.1381

  15. Lopes CDH, Antonacio FF; Moraes PMG, Harada G, Gadia R, Jardim DLF, Katz A, Sandoval RL, Achatz MIADSW, Castro Jr G. Molecular profile and clinical data of patients with lung cancer harboring germline TP53 R337H mutation. Annals of Oncology (2021) 32 (suppl_5): S1227-S1236. 10.1016/annonc/annonc681. ESMO 2021.
    Link: https://doi.org/10.1016/j.annonc.2021.08.268

  16. Harada G, Falcon CJ, Santini FC, Chang JC, Yang SR, Arcila ME, Rekhtman N, Drilon A. Splicing factor mutant lung cancers: A comprehensive molecular and clinicopathologic characterization. AACR 2022
    Link: https://doi.org/10.1158/1538-7445.AM2022-868

  17. Lamoureux AA, Fisher M, Lemelle L, Pfaff E, Kramm C, De Wilde B, Kazanowska B, Hutter C, Pfister SM, Sturm D, Jones D, Orbach D, Pierron G, Raskin S, Drilon A, Diamond E, Harada G, Zapotocky M, Ellezam B, Weil AG, Venne D, Barritault M, Leblond P, Coltin H, Hammad R, Tabori U, Hawkins C, Hansford JR, Meyran D, Erker C, McFadden K, Sato M, Gottardo NG, Dholaria H, Nørøxe DS, Goto H, Ziegler DS, Lin FY, Parsons DW, Lindsay H, Wong TT, Liu YL, Wu KS, Franson AF, Hwang E, Aguilar-Bonilla A, Cheng S, Cacciotti C, Massimino M, Schiavello E, Wood P, Hoffman LM, Cappellano A, Lassaletta A, Van Damme A, Llort A, Gerber NU, Ceruso MS, Bendel AE, Skrypek M, Hamideh D, Mushtaq N, Walter A, Jabado N, Alsahlawi A, Farmer JP, Abadi CC, Mueller S, Mazewski C, Aguilera D, Robison N, O’Halloran K, Abbou S, Berlanga P, Geoerger B, Øra I, Moertel CL, Razis ED, Vernadou A, Doz F, Laetsch TW, Perreault S. HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion. Neuro Oncol. 2022 Jun 3;24(Suppl 1):i61–2. doi: 10.1093/neuonc/noac079.226. PMCID: PMC9164744.
    Link: https://doi.org/10.1093/neuonc/noac079.226

  18. Guilherme Harada, Noura J. Choudhury, Alison M. Schram, Ezra Rosen, Yonina R. Murciano-Goroff, Christina J. Falcon, Clare Wilhelm, Lauren A. Kaplanis, Dazhi Liu, Jason C. Chang, Soo-Ryum Yang, Aradhika Dhawan, Patrick Evans, Casey Savin, Grace Grimaldi, Ronak H. Shah, Emiliano Cocco, and Alexander E. Drilon. Mechanisms of acquired resistance to TRK inhibitors. Journal of Clinical Oncology 2022 40:16_suppl, 3104-3104. ASCO 2022.
    Link: https://doi.org/10.1200/JCO.2022.40.16_suppl.3104

  19. Or Kalchiem-Dekel, Christina J. Falcon, Christine M. Bestvina, Dazhi Liu, Lauren A. Kaplanis, Clare Wilhelm, Jordan Eichholz, Guilherme Harada, Lori J. Wirth, Robert P. Lee, David Kadosh, Robin B Mendelsohn, Jessica Donington, Justin F. Gainor, Alexander E. Drilon, and Jessica Jiyeong Lin. Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy. Journal of Clinical Oncology 2022 40:16_suppl, 9080-9080. ASCO 2022.
    Link: https://doi.org/10.1200/JCO.2022.40.16_suppl.9080

  20. Guilherme Harada, Byoung Chul Cho, Jessica J. Lin, D. Ross Camidge, Vamsidhar Velcheti, Benjamin Solomon, Shun Lu, Ki Hyeong Lee, Sang-We Kim, Steven Kao, Rafal Dziadziuszko, Muhammad Beg, Misako Nagasaka, Enriqueta Felip, Benjamin Besse, Christoph Springfeld, Sanjay Popat, Jürgen Wolf, Denise Trone, Shanna Stopatschinskaja, Alexander Drilon. Pivotal data update from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced
    non–small cell lung cancer (NSCLC).     2023 Targeted Therapies of Lung Cancer Meeting.
    Link: https://ttlc2023.iaslc.org/wp-content/uploads/2023/02/TTLC2023-Program-Book.pdf

  21. Karthigayini Sivaprakasam, Guilherme Harada, Noura J. Choudhury, Casey Savin, Ronak H. Shah, Michael F. Berger, Alexander E. Drilon. ctDNA analysis of NTRK fusion and mechanisms of acquired resistance to TRK inhibitors. ASCO 2023
    Link: https://doi.org/10.1200/JCO.2023.41.16_suppl.3062

  22. Noura J. Choudhury, Guilherme Harada, Karissa Whiting, Ronglai Shen, Soo-Ryum Yang, David B. Solit, Michael F. Berger, Sara Dinapoli, Ghassan K. Abou-Alfa, Gopa Iyer, Alexander E. Drilon, James J. Harding, Alison M. Schram. Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository. ASCO 2023
    Link: https://doi.org//10.1200/JCO.2023.41.16_suppl.3074

  23. Harada, F. Santini, R. W. Repetti, J. Chang, S.R. Yang, Y.-T. Lin, K. A. Moses, C. Falcon, C. J. Wilhelm, M. Goldstein, A. Makhnin, M. S. Ginsberg, A. J. Plodkowski, M. Kris, A. Drilon. Phase II Study of Cabozantinib in Patients with MET-Altered Lung Cancers. ESMO 2023
    Link: https://doi.org/10.1016/j.annonc.2023.09.2417

Capítulos de livros

Cardiologia do exercício - do atleta ao cardiopata 4ª Edição

Hoff, PMG., Santos, LS., Testa, L., Harada, G. (2019). Physical Exercise in cancer prevention. Editors: Negrão C, Pereira Barretto A, Rondon MUPB.  Exercise Cardiology, 4th ed. Sao Paulo-Brazil: Manole.

Saiba mais

Emergências em Clínica Médica

Hoff, PMG., Santos, LS., Testa, L., Harada, G. (2019). Physical Exercise in cancer prevention. Editors: Negrão C, Pereira Barretto A, Rondon MUPB.  Exercise Cardiology, 4th ed. Sao Paulo-Brazil: Manole.

Saiba Mais